Intravesical chemo-immunotherapy in non muscle invasive bladder cancer

D. LEOPARDO¹, S.C. CECERE¹, M. DI NAPOLI¹, C. CAVALIERI¹, C. PISANO¹, S. STRIANO², L. MARRA², L. MENNA², L. CLAUDIO², S. PERDONÀ², S. SETOLA³, M. BERRETTA⁴, R. FRANCO⁵, R. TAMBARO¹, S. PIGNATA¹, G. FACCHINI¹

¹Uro-Gynecologic Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Napoli, Italia
²Urologic Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Napoli, Italia
³Radiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Napoli, Italia
⁴Department of Medical Oncology, National Cancer Institute - IRCCS, Aviano, Italy
⁵Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Napoli, Italia

Corresponding Author: Sandro Pignata MD, Ph.D; e-mail: s.pignata@istitutotumori.na.it

Abstract. – Non-Muscle-Invasive-Bladder-Cancer represents 75-85% of the new bladder cancer cases per year. Trans-urethral vesical resection is the milestone for diagnosis and therapy. After primary treatment, recurrence is frequent depending on the presence of several established risk factors: multiplicity, T dimension, prior recurrence. In some patients disease progress to an advanced stage. Adjuvant chemo-immunotherapy has been widely used depending on the risk category assigned on the basis of the risk factors for recurrence. In low risk categories a one shot treatment with chemotherapy is considered the standard treatment without any maintenance therapy. In intermediate risk patients, adjuvant induction therapy and maintenance chemotherapy or immunotherapy for at least one year is recommended. In high risk patients adjuvant induction and maintenance immunotherapy until 3 years is considered the best strategy.

In this review data on the different drugs used in this setting will be discussed.

Key Words: Bladder cancer, Mytomycin C, BCG, Doxorubicin, Gemcitabine.

Introduction

Bladder carcinoma (BC) is the most common tumour of the urinary tract¹. In 2006, 104,400 incident cases of bladder cancer were diagnosed in Europe, of which 82,800 were found in men and 21,600 in women¹. It is a disease that peaks during the third age and urothelial histology is present in about 90% of the cases¹. This represents 6.6% of the total cancers in men and 2.1% in women, with an estimated male:female ratio of 3.8. In men, bladder cancer is the fourth most common cancer resulting in 4.1% of total cancer deaths². The mortality is declining in the last fifteen years probably due to change in lifestyle and safety of the work environment³.

Tobacco smoking is the single best recognized risk factor for bladder cancer⁴, with an estimated attributable risk proportion of 55% in men and 19% in women in northern Italy⁵. Occupational exposure to aromatic amine, polycyclic aromatic hydrocarbons, dyestuff printing and rubber manufacture were found to be responsible for about 4% of bladder cancer cases⁵, while the role of inflammation and urinary tract infections is controversial⁶. Vegetables and fruit rich diet have been associated in a metanalysis of 38 studies with a favourable relative risk of 0.7 and 0.8, respectively⁷. The role of hair dyes or coffee drinking habits is still debated⁸-¹⁰.

BC is often diagnosed at an early stage; in the United States during the year 2003, 47% of bladder cancer new cases were stage 0, 22% stage I, 11% stage II, 5% stage III and 6% stage IV¹¹.

Non-Muscle-Invasive-Bladder-Cancer (NMIBC) (pTa, pT1, carcinoma in situ) represents 75-85% of the new cases¹², with 70% pTa, 20% pT1 and 10% of carcinoma in situ (CIS)¹³. Most NMIBC (60-70%) have a trend for recurrence after transurethral vesical. Some are at high risk for progression to muscle invasion¹⁴.
Risk Factor for Recurrence

According to a meta-analysis of 19 studies\textsuperscript{15} in 2596 patients treated with different drugs and regimens\textsuperscript{16} the most important risk factors for recurrence are the number of synchronous tumours, previous NMIBC and tumour size. From these data it is possible to score patients in 3 groups (low, intermediate and high risk of recurrence); low risk group has a recurrence rate at 5 years of 31% while high recurrence group has a recurrence rate of 78%. Other authors, according to Fernandez-Gomez et al (CUETO Club Urológico Español de Tratamiento Oncológico)\textsuperscript{17,18}, categorize patients according to the presence of 4 risk factors (multiplicity, female gender, prior tumour, presence of carcinoma in situ).

Risk Factors for Progression

Progression to muscular invasive cancer is less frequent than recurrence: at 5 years, progression is reported up to 45% of the cases, depending on the different category risk groups\textsuperscript{15}. According to Sylvester et al\textsuperscript{18}, the most important risk factors for progression are T category, presence of concomitant CIS, tumor grade, resulting in an EORTC (European Organisation for Research and Treatment of Cancer) score that assigns NMIBC disease to three different progression risk categories (low, intermediate and high risk of progression). Moreover, Fernandez et al\textsuperscript{17} found in a multivariate analysis that recurrence at first cystoscopy, stage, grade, and an history of recurrent disease are the most important progression prognostic factors: in this analysis the presence of concomitant CIS at first diagnosis was statistically significant only at univariate analysis. The role of molecular markers has not been fully explored: according to some data expression of fibroblast growth factor receptor 3 (FGFR3) seems correlated to a favorable prognosis\textsuperscript{19-21}. The assignment of patients to a specific risk category for recurrence or progression is considered crucial for the choice of the adequate adjuvant intravesical therapy (Table I).

Surgical Treatment

Trans urethral resection (TUR) represents the first step for diagnosis and treatment\textsuperscript{22-25}. It should be performed with complete excision of NMIBC until deep muscle. A single resection is acceptable for lesion less of 1 cm, while multiple treatments are needed for larger lesions. Residual tumor after resection of the T1 cases was found in 33-53%\textsuperscript{26-31}. The results of an EORTC phase 3 study, showing a wide range of recurrence rate in multifocal NMIBC among the several centers involved in the trial (7-46% at 3 months), suggest a difference in TUR effectiveness in the different institutions\textsuperscript{32}. In a recent study re-TUR was performed in 83 patients. Residual tumor was found in 53% of pT1 and in 27% of pTa NMIBC, often in the same site of the previous resection (81%)\textsuperscript{33}. In pT1 NMIBC the prognosis largely depends on the pathology at time of the second TUR. Re-TUR is considered important also to predict response to adjuvant treatment. In fact,

<table>
<thead>
<tr>
<th>Risk Category for recurrence</th>
<th>Probability of recurrence at 1 year</th>
<th>Probability of recurrence at 5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>15%</td>
<td>31%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>24-38%</td>
<td>46-62%</td>
</tr>
<tr>
<td>High</td>
<td>61%</td>
<td>78%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk Category for progression</th>
<th>Probability of recurrence at 1 year</th>
<th>Probability of recurrence at 5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>0.2%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>1%</td>
<td>6%</td>
</tr>
<tr>
<td>High</td>
<td>5-17%</td>
<td>17-45%</td>
</tr>
</tbody>
</table>

Main Parameters used to define risk categories for recurrence and progression Tumour number: Single; 2-7; >8 Tumour diameter: <3 cm; >3 cm Prior recurrence rate: Primary; <1 recurrence/year; >1 recurrence/year Stage: Ta vs. T1 Concurrent CIS: No vs Yes Grade (WHO 1973): G1; G2; G3.
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer

according to Herr et al\textsuperscript{34}, there was a better response to BCG after a re-TUR than in patients that received only one TUR, probably due to a more radical surgery and accurate staging\textsuperscript{35}. A re-TUR is considered mandatory if the first TUR is incomplete, with the absence of muscle in the specimen, and in case of multiple, large, pT1, G3, high risk NMIBC\textsuperscript{12}. Excluded from re-TUR are the patients with TaG1 at diagnosis and multiple recurrent TaG1. Re-TUR is recommended 2-6 weeks after the TUR and should include a resection in the site of previous tumor\textsuperscript{12}. Immediate radical cystectomy should always be considered for NMIBC high risk patients, including those with multiple recurrent high grade tumor, pT1 high grade tumor, high grade tumors with concomitant CIS, particularly after BCG failure. Some data suggest that deferred cystectomy may decrease disease-specific survival\textsuperscript{37}.

Intravesical Medical Treatment of NMIBC

In this section we review the clinical data available regarding the intra-vesical medical treatment of NMIBC. Data are based on a PUBMED search performed in February 2013.

Mitomycin C (MMC)

MMC is an antibiotic with a not completely clear mechanism of action, but mostly working as an alkylating agent\textsuperscript{38}. The drug acts inhibiting DNA synthesis by induction of internal cross links. MMC has an high molecular weight (334 kDa) and, therefore, it is an ideal intravesical agent due to its very low systemic adsorption (about 1%) through the umbrella cell layer, with rare systemic side effects\textsuperscript{39}. Myelosuppression is rare (0.7%)\textsuperscript{40}, while chemical cystitis is the most frequent side effect being reported in 41% of the cases\textsuperscript{41}. Allergic and skin reactions (in 9.8% of the patients) may occur after the second instillation as a delayed hypersensitivity reaction\textsuperscript{41}.

MMC has been assessed as single agent versus TUR alone in several trials, in different setting and treatment modalities (different risk groups, as single instillation after TUR, as maintenance therapy). Also, MMC has been tested at doses ranging from 20 to 60 mg in diluted in 0.9% saline solution and in a concentration ranging from 0.5 to 2 mg/ml\textsuperscript{42}.

From the early 80’s MMC has been used in several phase I-II studies including low and high risk patients\textsuperscript{33,45}. In one of these after a median follow-up of 18 months 70% of patients was disease-free with a median duration of response of about 14 months\textsuperscript{35}. In a meta-analysis of 5 controlled studies and 859 patients treated with MMC it appears that MMC treatment induces an overall advantage of 15% in term of short term recurrence rate compared to TUR alone (37 vs. 52%), although at 5 years the recurrence rate was similar\textsuperscript{46}. Later on a phase III randomized trial\textsuperscript{45}, 502 patients were randomized in 3 arms: no treatment after TUR, a single instillation (40 mg) within 24 hours post-TUR and an early instillation followed by four consecutive 40 mg instillations every three months. An initial reduction in recurrence rate was demonstrated in the third arm with an improvement in disease free interval, although after a 7-years follow up the advantage was not statistically significant compared to a single early instillation, indicating the ineffectiveness of maintenance therapy\textsuperscript{44}.

However, the role of maintenance therapy is still debated with discordant data coming from several metanalisys and controlled trials. Nilsson et al\textsuperscript{46} analyzed 1774 patients in 9 randomized trials, showing an absolute benefit of 16% in term of reduction in recurrence rate for maintenance therapy (38 vs. 54%), while Solsona et al\textsuperscript{46}, in two consecutive randomized EORTC trials, investigating the role of maintenance chemotherapy (MMC 30 mg, and doxorubicin 50 mg) for 6 months (short maintenance) or for 1 year (long maintenance), was not able to identify any advantage for the maintenance groups in term of recurrence rate reduction compared to an initial single early instillation made immediately (within 24 hours) after TUR. One of the limits of these prospective trials aimed to show an advantage in short and long term recurrence rate for maintenance MMC is the enrollment in the trials of patients with different risk categories.

Other trials have investigated the effectiveness of MMC in specific sub-setting of NMIBC.

In low risk NMIBC data are available for MMC as an early single instillation. In a non recent prospective trial 131 low risk NMIBC patients were randomized to receive a single early instillation of 30 mg MMC or no therapy post-
TUR. At a short term follow up of 24 months adjuvant treatment arm was able to prolong the recurrence-free interval, although at a longer follow-up of 48 months no statistical difference was observed. On the other end, in a recent meta-analysis conducted by Sylvester et al., with several controlled studies and 427 NMIBC patients treated with MMC, the authors conclude that MMC administrated within 24 hours after TUR reduces the recurrence rate compared to TUR alone (36.7 vs. 48.4%). In a study a positive effect, although small, was observed also in multifocal tumours.

In the intermediate risk setting a randomized trial compared an early single MMC instillation with maintenance repeated treatments. No statistically difference was found between the two groups in term of reduction of recurrences in these intermediate risk NMIBC patients.

The timing of MMC administration after TUR seems important. A very early administration of MMC, within 24 hours from TUR and even earlier within 6 hours or during TUR, seems to correlate with a significant better effect on the reduction of early recurrences both in low and intermediate risk NMIBC. In a trial, 131 low risk patients (3 cm or less single, papillary, primary or recurrent tumor) were randomized to receive a single immediate instillation MMC (30 mg) or TUR alone. At 1 year all patients were recurrence free, at 2 years of follow-up an advantage in favor of the immediate instillation was present, while no statistically significant difference was present at a longer follow-up. Absolute contraindication to an early instillation is represented by a real or suspected bladder perforation during TUR, while a relative contraindication is represented by a deep and wide resection during TUR with significant bleeding.

Also different modalities of MMC administration have been investigated. A randomized trial by Au and coworkers, tested MMC instillation in specific conditions; the hypothesis was to improve MMC effectiveness by increasing the bladder concentration through the alkalinization with sodium bicarbonate of the urine and a decrease of the bladder flow through ultrasound controlled catheterization. In this study 230 patients were randomized to receive this experimental schedule at 40 mg dose versus a control arm with 20 mg weekly for 6 weeks. At a 5-years follow up the median time to recurrence was in favor of the experimental arm with alkaline urine (29.1 vs. 11.8 months) with an higher proportion of recurrence free patients (41 vs. 24.6%) in favor of the experimental arm with alkaline urine.

Another small study investigated the option of an intensive schedule of MMC instillation in 40 intermediate risk NMIBC patients that underwent 3-time per week administration for 2 consecutive weeks after TUR. Low local and systemic toxicity was found, with interesting results in term of recurrence free rate and median time to recurrence; prospective trials are needed to confirm these data.

According to some authors MMC is considered potentially superior to the other chemotherapy agents in reducing recurrence rate. However, prospective trials directly comparing different chemotherapy agents are scanty in the literature.

In conclusion, MMC is safe and seems effective in low and intermediate risk NMIBC patients being able to decrease the recurrence rate when given as an early instillation after TUR. Discordant data are available regarding the role of maintenance therapy (one to three years) versus shorter therapy (6 weeks or longer). Maintenance was found ineffective in reducing progression rate and it seems to confer only a small advantage in reducing recurrence rate.

Mitomycin Electromotive

The electromotive administration of MMC (EMDA) is a method to improve absorption of the drug through the interstitial cell layer. An electric current (about 15-30 mAmpere) is delivered in order to increase cell layer permeability. In vitro experiments have shown higher cell concentration of the drug compared to normal intravesical instillation.

In a phase II study (28 multifocal pTa-1, G1-2 NMIBC patients) EMDA (MMC 40 mg in 20 min with 15 mA electricity) has been compared to weekly 40 mg MMC instillation for 8 weeks with an advantage in term of reduction of recurrence rate (60% vs. 33%).

In another prospective trial, 108 patients with multifocal CIS were randomized in three arms: 6 weeks of 40 mg MMC passive diffusion for 60 minutes, 6 weeks electromotive administration for 30 minutes (MMC 40 mg 20mA) and 6 weeks of 81 mg BCG instillations for 120 minutes. Responders patients (complete response at cystoscopy and urinary cytology at 3 and 6 months) completed 10 months of maintenance therapy. Similar results were achieved with EMDA (complete response rate...
at 3 and 6 months 53% and 58%, respectively) and BCG (56% and 64%), both with a statistically significant difference versus MMC passive diffusion (28%, \( p = 0.036 \) and 31%, \( p = 0.012 \)). At a median follow-up of 82 months the authors reported no difference in term of recurrence-free interval (35 months for MMC EMDA, 26 months for BCG and 19.5 months for MMC passive), progression to invasive cancer, cancer specific and overall mortality between MMC electromotive administration and BCG. The authors reported also lower local toxicity of electromotive administration versus BCG$^{62}$.

On the hypothesis that BCG-induced inflammation may increase MMC uptake, a prospective trial has been performed with the combination. Two-hundred-twelve NMIBC pT1 patients were randomized to receive 6 weekly instillations of BCG 81 mg or 3 cycles of a sequential schedule (2 weeks BCG followed by an electromotive administration of MMC) with overall 9 instillations. Recurrence free patients after induction therapy underwent maintenance therapy for 10 months with the same schedule. At a median follow-up of 88 months the experimental arm showed an higher disease free interval (69 vs. 21 months, \( p = 0.001 \)) and lower recurrence rate (41.9 vs. 57.9%, \( p = 0.001 \)), with a further advantage in terms of reduction of progression (9.3 vs. 21.9%, \( p = 0.004 \)), cancer specific mortality (5.6 vs. 16.2%, \( p = 0.011 \)) and overall survival (21.5 vs. 32.4%, \( p = 0.453 \))$^{63}$.

Electromotive administration of MMC has also been tested as neoadjuvant treatment for low risk NMIBC patients. One-hundred-sixty-seven NMIBC pTaG1-G2 patients were randomized in three arm: TUR alone, a single MMC (40 mg) instillation before TUR and a single electromotive administration (MMC 40 mg in 30 min at 20mA) before TUR. At a median follow-up of 84.7 months the authors demonstrated a significant advantage for experimental arm in term of reduction of recurrence rate and of disease free interval$^{64}$.

These interesting results need to be validated in multicentre clinical trials with an adequate sample size before electromotive MMC can be adopted as a standard treatment in NMIBC.

**Antracyclines**

Antracyclines, doxorubicin and its derivative epirubicin, are chemotherapeutic agents prescribed as intravesical treatment in NMIBC. These drugs are not cycle specific and their mechanism of action consists in the inhibition of Topoisomerase II.

Doxorubicin and epirubicin have a similar molecular weight of 580 kDa, and thus absorption and systemic toxicity is extremely rare; doxorubicin seems to be more toxic than epirubicin due to the more frequent appearance of chemical cystitis (28.8%), allergic reactions (0.3%), gastrointestinal side effects (1.7%) and fever (0.8%)$^{61}$.

Doxorubicin is used in a dose ranging from 30 to 100 mg with a weekly or three weekly schedule (42). Doxorubicin has been tested in several studies and overall, a 18% reduction in tumor recurrence has been described compared to untreated controls$^{68-75}$. On the contrary, maintenance therapy (up to 2 years) was not superior to 6 weekly instillations of 50 mg doxorubicin in term of reduction of recurrences$^{76}$. Doxorubicin has not been found effective in reducing tumor progression$^{75}$.

Reduction in recurrence rate with weekly or a single dose post-TUR doxorubicin instillation has been demonstrated in many prospective trials$^{62,71-81}$.

In a phase I-II study in CIS G3 NMIBC patients, epirubicin (at escalating doses of 30, 50 and 80 mg) induced 70% of cases recurrence free, with a mean duration of complete remission of 22.4 months (range 7-50 months)$^{82}$. In a randomized trial the two anthracyclines have been compared in 114 patients treated over a 1-year period. At the 1 and 2 year follow up there was no statistically difference in term of tumor-free rate$^{83}$.

Another trial compared the effectiveness of the two anthracyclines randomized 253 patients in 4 arms: epirubicin 50 mg, epirubicin 80 mg, doxorubicin 50 mg for 8 consecutive weeks, no treatment after TUR and monthly maintenance for 1 year. Recurrence rates were 25, 17.6, 36.7 and 65.6%, \( (p < 0.05 \) in favor of both doses of epirubicin) with a mean recurrence free interval of 16, 15.4, 18.9 and 6.3 months. Epirubicin induced a lower toxicity than doxorubicin even if utilized at the higher dose$^{84}$.

The effectiveness of epirubicin has been shown also as an early (within 24 hours) single post TUR instillation. Epirubicin has been proposed as the standard treatment for low risk NMIBC and as a treatment option for intermediate and high risk NMIBC with a reduction of 39% in recurrence rate according to the main meta-analysis$^{52}$.

However, data regarding the reduction in recurrence rate in intermediate risk NMIBC are scanty.

In one study$^{84}$ an early single epirubicin 50 mg instillation within 6 hours from TUR was poorly effective in tumor larger than 5 mm. In another randomized multicenter trial in 219 low/intermediate risk NMIBC, an early single epirubicin 80 mg instillation post TUR versus TUR alone with-
studies showing that the maximum doses utilized (2000 mg total 40 mg/mL in a 50 mL volume) is effective with a favorable toxicity profile due to minimal systemic absorption. In phase I studies no grade 4 hematological toxicity was recorded while hematuria, dysuria, headache, fatigue, hand-foot syndrome, hypogastric discomfort and grade 1 bladder spasms were reported.

A phase 2 multicenter study investigated the effectiveness, local and systemic tolerability of gemcitabine. One-hundred-sixteen intermediate and high risk NMIBC patients (refractory and not refractory to BCG) were treated with gemcitabine 2000 mg weekly schedule for 6 weeks after TUR. Twelve% of the patients reported urinary urgency, 5.1% dizziness and slight fever, 0.8% abdominal pain with ulcerative lesions at cystoscopy. At 1 years follow-up 74.6% of patients were disease free, while recurrences were observed in 25.4% of the cases, with a mean recurrence free time of 7 months. At univariate analysis the drug was more effective in NMIBC patients at first diagnosis ($p = 0.04$), in untreated cases ($p = 0.03$), and pTa patients ($p = 0.0018$). In BCG refractory patients the authors reported a complete response rate of 75% in intermediate risk NMIBC (24 patients) and of 43.7% in high-risk NMIBC (16 patients). In another phase 2 study only in BCG refractory NMIBC patients, 30 patients underwent a twice weekly gemcitabine (2000 mg) instillation for three consecutive weeks, for two times with a week of rest. Patients were evaluated at 8 weeks, then every 3 months for 1 year. At a median follow-up of 19 months, 50% of the patients were in complete remission, 0.8% of the patients were in complete response with a 1-year recurrence-free survival rate of 21%, while relapsed patients had a median recurrence free survival time of 3.6 months. Twenty-one% of the complete responders patients were recurrence free at 1 year with a time to recurrence of 19 months. Finally, 11 patients underwent to radical cystectomy.

Shorter schedules of gemcitabine instillation were tested in Ta-T1 G1-2 (low or intermediate risk) NMIBC. Twenty-eight patients underwent 2000 mg gemcitabine. The complete response rate was 46.6% (absence of macroscopic residual lesion at cystoscopy after six weeks from the first instillation and negative urinary cytology). The median time to first recurrence was 9.1 months, with 32.2% of the patients recurrence free at 1 year.

A chemo-immunotherapy combination showed interesting results in a preliminary prospective
study. Fifty-nine percent of the patients were treated with 6 weeks BCG instillation while the remaining patients were treated with two gemcitabine instillations, the first immediately after TUR (1000 mg), and another a week later (2000 mg), followed by 6 weeks of BCG instillations. A median recurrence free period of 24 months was observed in the combination arm compared to 19 months in the BCG arm. At 6 and 9 months chemo-immunotherapy showed a lower recurrence rate, but no difference between the two arms was found at a longer follow up. These data suggest that gemcitabine-BCG combination is a promising strategy to prevent early relapse and to increase recurrence free period\(^8\). More data are needed.

Gemcitabine effectiveness in BCG refractory NMIBC has been investigated in several trial. In a randomized phase III trial gemcitabine (6 weekly instillations) was compared to MMC (4 weekly instillations), followed in both arms by 10 monthly instillations of maintenance therapy in responding patients. At a follow-up of 36 months, out of 109 evaluable patients 72% (39/54) in gemcitabine arm were recurrence-free versus 61% (33/55) in MMC group. MMC arm also showed an higher progression rate than gemcitabine in recurrent patients and worse tolerability (higher chemical cystitis rate). According to these authors gemcitabine represents a preferable option in BCG-refractory NMIBC compared to MMC\(^9\).

In conclusion, gemcitabine is another intravesical chemotherapeutic agent with mild toxicity. It has been investigated in intermediate/high risk patients with interesting results. Gemcitabine seems to be more effective than MMC in BCG-refractory NMIBC. The interesting schedule with combined chemo-immunotherapy needs larger randomized trials.

**BCG**

Intravesical immunotherapy is based on BCG (Bacillus-Calmette-Guerin) instillations after TUR. BCG is a modified strain of Mycobacterium Bovis that is able to induce an immunoreaction after contact with bladder cells; the real anticancer mechanism is not yet well known. Different routes of BCG administration (percutaneous, intravesical injection, oral, intravesical and percutaneous combination) have been tested in several studies. Combined intravesical and percutaneous combination was to be found superior to intravesical BCG alone in randomized studies\(^96-98\). Local and systemic side effects occur more frequently with intravesical BCG therapy than in patients treated with chemotherapy, as reviewed by Lamm\(^96\), Witjes\(^100\), Houghton\(^101\). About 75% of patients treated experience chemical cystitis, haematuria and irritative voiding symptoms. Less frequently infections, as prostatitis and epididymo-orchitis, have been described with the need of BCG withdrawal. About 40% of patients suffers of systemic side effects as flu-like syndrome and fever and rarely sepsis. It is necessary to interrupt BCG administration in about 20% of cases. Most side effect appears during the induction therapy and in the first part of maintenance. According to several studies only one third of patients was able to complete the 36-months treatment. Absolute contraindications to BCG treatment are the occurrence of traumatic catheterization, TUR within previous two weeks (risk of systemic infection), macroscopic haematuria, urethral stenosis, prior BCG related sepsis, immunosuppression, urinary tract infection, active tuberculosis\(^102\), Anti-tubercular concurrent antibiotic treatment should not be prescribed since it can reduces BCG effectiveness. Ofloxacin and isoniazid have been proposed as prophylactic administration to reduce side effects. In a double blind trial versus placebo, 115 patients were treated with ofloxacin, a fluoroquinolone, that was found to be particular effective in reducing the moderate and severe adverse events\(^103\). Some trials have explored the reduction of the dose in patients intolerant to the full dose. In an initial study, 500 patients of all stages and grades were treated with a full BCG (81 mg) dose compared to one-third of the dose, for 12 instillations. The reduced dose showed a better toxicity profile, but it was not found equally effective in high risk patients compared to the full dose\(^103\). This data were in contrast in accordance with those fonded in a smaller study in which similar effectiveness was found between 81 mg and 27 mg\(^103\). Another trial in 430 intermediate risk patients compared 12 weekly BCG instillations at the dose of 27 mg, or 13,5 mg compared to 30 mg MMC. The lower dose was found not effective, while the 27 mg BCG dose was more toxic than MMC. BCG is derived from different strains and in some studies no difference was found among them in terms of effectiveness and toxicity\(^104-106\). The hypothesis that early occurrence of local or systemic side effects leads to a longer time to first recurrence has not been confirmed in clinical trials\(^107\).

BCG is usually administrated 3-4 weeks after TUR as an induction therapy of 6 weeks followed by a maintenance period of 3 consecutive weeks every 3 or 6 months at variable duration from 1 to 3
years\textsuperscript{108,109}. BCG reduces recurrence rate versus TUR alone\textsuperscript{110,111} and it is superior to chemotherapy according to the main meta-analysis\textsuperscript{112-115}. Data indicate that the maintenance period is needed to obtain an advantage of 32% versus MMC in terms of recurrence and progression risk. In the Sylvester’s meta-analysis\textsuperscript{116} with 4863 patients from more than 20 randomized trials with BCG, the reduction in progression rate has been observed only in the trials where maintenance treatment was given. At a median follow up of 2.5 years only 9.8% of the patients under BCG maintenance treatment progressed versus 13.8% in the control arms. Maintenance BCG treatment was found particularly effective in papillary intermediate-high risk NMIBC (only 6% progressed) and in patients with CIS (only 14% progressed)\textsuperscript{116}. BCG maintenance was found very effective in patients with CIS compared to MMC and other chemotherapeutic agents. In a recent meta-analysis with 700 CIS patients it has been underlined that BCG allows short and long term advantages compared to chemotherapy with a complete response rate of 68% versus 51% ($p = 0.0002$)\textsuperscript{117}. In these patients the recurrence rate was in favor of BCG compared to chemotherapy. At a median follow up of 3.6 years 47% of BCG maintenance patients were disease free versus 26% of those treated with chemotherapy. Furthermore, 40-60% of patients who failed after BCG induction treatment responded to a second BCG induction treatment\textsuperscript{117}.

In conclusion, in intermediate risk NMIBC BCG maintenance treatment for one to three years has an higher activity compared to chemotherapy, particularly in pretreated and recurrent patients.

In high risk patients, BCG maintenance treatment is able to prevent tumor relapse and progression in a significant proportion of patients. In the cases with carcinoma in situ, although BCG is effective, the option of radical cystectomy should always be taken into account\textsuperscript{108}.

**Expert Commentary**

Although bladder carcinoma is often diagnosed at an early stage (NMIBC) there is an high rate of recurrences and progressions to invasive cancer. TUR is crucial for both diagnosis and management of NMIBC; it is needed to plan therapy according to grade, histology and deep muscle involvement. Adjuvant therapy is prescribed to reduce the recurrence rate (31-78% at 5 years) and progression risk (1-45% at 5 years). Re-TUR is strongly recommended in T1 NMIBC particularly when the resec-

ation has not reached the deep muscle.

The choice of an adjuvant therapy depends on the risk category for recurrence and progression. Guidelines for treatment are available (Table II).

Early one shot therapy within 6-24 hours after TUR is effective in reducing recurrence rate in low risk NMIBC patients, where no further treatment seems needed.

In patients with NMIBC at intermediate risk for recurrence one year maintenance immunotherapy or chemotherapy is recommended, the choice depends on the risk category assigned. In these patients chemotherapy was found effective in reducing the risk of recurrence but not the risk of progression. One early pill therapy within 24 hours after TUR (better within 6 hours) was found the best schedule for almost all the chemotherapy agents investigated in order to reduce the risk of recurrence. The real role of chemotherapy maintenance on progression is debated and data do not support this strategy. In patients at intermediate risk of recurrence and at high risk for progression maintenance immunotherapy probably confers an higher effectiveness compared to chemotherapy.

NMIBC patients at high risk of recurrence and progression have to be treated with BCG immunotherapy with maintenance prolonged up to 3 years, although early cystectomy in several cases may be a lifesaving option.

In patients recurrent after BCG failure gemcitabine treatment seems more effective than MMC when a contraindication to cystectomy is present.

The schedules of treatment with sequential chemo-immunotherapy and electro-modulated MMC seems very promising but need larger trials.

**Five Years View**

New urine molecular marker tests are under investigation for initial diagnosis, early detection of the recurrence and as predictive factor for response to intravesical therapy; NMP22, Immucyt and Urovysion seems the more close to the clinical practice\textsuperscript{117}. Fluorescence-guided transurethral resection based on 5-aminolevulinic acid is a promising technique able to reduce the residual tumor tissue after TUR and possibly to determine a decrease in recurrence rate\textsuperscript{120}.

Promising new drugs and schedules of adjuvant intravesical therapy are under investigation. Immune-chemotherapy and EMDA MMC combined with BCG are in an advanced phase of investigation; other newer combinations including
Table II. Recommendations for adjuvant therapy in TaT1 tumours and for therapy of CIS according to EAU guidelines.

<table>
<thead>
<tr>
<th>EAU GUIDELINES 2011</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The type of intravesical therapy should be based on the risk groups shown</td>
<td>A</td>
</tr>
<tr>
<td>In patients with TaT1 tumours at low risk of recurrence and progression, one immediate instillation of chemotherapy is recommended as the complete adjuvant treatment</td>
<td>A</td>
</tr>
<tr>
<td>In patients with TaT1 tumours at intermediate or high risk of recurrence and intermediate risk of progression, one immediate instillation of chemotherapy should be followed by a minimum 1 year of BCG treatment, or by further instillations of chemotherapy</td>
<td>A</td>
</tr>
<tr>
<td>If chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug during instillation by reducing fluid intake. The optimal schedule and the duration of the chemotherapy instillations remain unclear, but it should be given no more than 12 months.</td>
<td>B</td>
</tr>
<tr>
<td>In patients with TaT1 tumours at high risk of progression, intravesical BCG for at least 1 year is indicated</td>
<td>A</td>
</tr>
<tr>
<td>In patients with bladder CIS, intravesical BCG for at least 1 year is indicated.</td>
<td>A</td>
</tr>
<tr>
<td>In patients with CIS in the epithelial lining of the prostatic urethra, TUR of the prostate followed by intravesical instillations of BCG could be an option</td>
<td>A</td>
</tr>
<tr>
<td>Immediate radical cystectomy may be offered to patients at highest risk of tumour progression</td>
<td>C</td>
</tr>
<tr>
<td>In patients with BCG failure, cystectomy is indicated</td>
<td>B</td>
</tr>
</tbody>
</table>

BCG-Interferonα-2B, RAD001-Gemcitabine, BGC-Sunitinib are now tested in ongoing trials. Also a new derivative strains from bacillus tuberculosis, the EN3348 (Mycobacterial Cell Wall-DNA Complex), is compared to MMC in BCG-failure setting in an ongoing clinical trial.

Conflict of Interest
The Authors declare that they have no conflict of interests.

Acknowledgements
The Authors thanks Dr. V Trocino, librarian of the National Cancer Institute of Naples.

References


Intravesical chemo-immunotherapy in non muscle invasive bladder cancer


85) WITVES JA, VAN DER HEIDEN AG, VREESMA JH, PETERS GJ, LAAN A, SCHALKEN JA. Intravesical gemcitabine: a
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer


NCI (National Cancer Institute USA) trials on going stage 0 bladder cancer http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=9340447&vers=2